Dark

Check out our API

EIGR
Eiger BioPharmaceuticals, Inc.
stock NASDAQ

Inactive

Apr 10, 2024

1.73USD-9.211%(-0.18)137,824

Pre-market

0.00USD-100.000%(-1.90)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 6, 2022

08:07AM EST UPDATE: Eiger Says 'Zokinvy MAA CHMP Opinion Expected H1'22' Benzinga

08:07AM EST UPDATE: Eiger Sees 'Phase 3 COVID-19 TOGETHER (Peginterferon Lambda) Study Topline Data H1'22' Benzinga

08:06AM EST UPDATE: Eiger Says 'Phase 3 HDV LIMT-2 (Peginterferon Lambda) Study Enrolling and Dosing' Benzinga

08:06AM EST UPDATE: Eiger Sees 'Phase 3 HDV D-LIVR (Lonafarnib) Study Topline Data Planned by End of 2022' Benzinga

08:06AM EST Eiger BioPharma Offers Expectations For 2022 Catalysts, Milestones Benzinga

08:02AM EST Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and PR Newswire

Jan 3, 2022

08:01AM EST Eiger BioPharmaceuticals to Present at H.C. Wainwright BioConnect 2022 Virtual PR Newswire

Dec 22, 2021

11:00AM EST Eiger Biopharma Sam.gov Contract Listing For $225K Contract With Dept. Of Veterans Affairs Benzinga

Dec 21, 2021

04:06PM EST Eiger BioPharmaceuticals Announces 1st Patient Enrolled In LIMT-2 Study Benzinga

04:05PM EST Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection PR Newswire

Dec 15, 2021

08:15AM EST Eiger Reports Positive Analysis & Continuation Of Dosing Of Peginterferon Lambda In Phase 3 Study Of COVID-19 Patients RTTNews

08:04AM EST Eiger BioPharma Reports Second Interim Analysis, Continuation Of Dosing Of Peginterfereon Lambda In Phase 3 TOGETHER Study OF Newly-Diagnosed COVID-19 Patients Benzinga

08:03AM EST Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Patients PR Newswire

Dec 1, 2021

08:02AM EST Eiger BioPharmaceuticals Announces Presentations at Upcoming HEP DART 2021 PR Newswire

Nov 10, 2021

08:04AM EST Eiger BioPharmaceuticals to Participate in Upcoming November 2021 Investor PR Newswire

Nov 5, 2021

09:26AM EDT Eiger BioPharmaceuticals Q3 EPS $(0.65) Misses $(0.56) Estimate Benzinga

Nov 4, 2021

04:02PM EDT Eiger BioPharmaceuticals Reports Third Quarter 2021 Financial Results and PR Newswire

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Nov 2, 2021

04:06PM EDT Eiger BioPharmaceuticals to Host and Webcast Virtual Key Opinion Leader Event PR Newswire

Nov 1, 2021

08:20AM EDT Eiger BioPharmaceuticals Announces Complete Enrollment Of D-LIVR, The Largest Phase 3 Study In Hepatitis Delta Virus, Investigating Lonafarnib, The Only Oral Agent In Development For HDV Benzinga

08:12AM EDT Eiger BioPharma Completes Enrollment In Phase 3 D-LIVR Study RTTNews

08:03AM EDT Phase 3 Study in Hepatitis Delta Virus (HDV), Investigating Lonafarnib, the Only Oral Agent in Development for HDV PR Newswire

Oct 21, 2021

04:06PM EDT Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2021 PR Newswire

Oct 7, 2021

12:54PM EDT Eiger BioPharmaceuticals Sponsored Study Titled 'Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV (LIMT-2)' Posted To ClinicalTrials.Gov; Study Not yet Recruiting Benzinga

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Oct 1, 2021

04:06PM EDT Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule PR Newswire

07:56AM EDT The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

08:03AM EDT Eiger BioPharmaceuticals Appoints Erik Atkisson as General Counsel and Chief PR Newswire

Sep 20, 2021

08:10AM EDT Eiger BioPharma Announces Interim Analysis Of Dosing Of Peginterferon Lambda In Phase 3 TOGETHER Study RTTNews

08:07AM EDT Eiger BioPharmaceuticals Announces Interim Analysis And Continuation Of Dosing Of Peginterferon Lambda In Phase 3 TOGETHER Study Of Newly Diagnosed COVID-19 Outpatients Benzinga

08:01AM EDT of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients PR Newswire

Sep 17, 2021

07:36AM EDT The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold Benzinga

Sep 16, 2021

07:48AM EDT The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study Benzinga

Sep 15, 2021

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

Sep 1, 2021

04:06PM EDT Eiger BioPharmaceuticals to Participate in Upcoming September 2021 Investor PR Newswire

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 9, 2021

08:40AM EDT Citigroup Maintains Buy on Eiger BioPharmaceuticals, Raises Price Target to $27 Benzinga

Aug 5, 2021

05:01PM EDT Eiger BioPharmaceuticals Q2 EPS $(0.57) Misses $(0.55) Estimate, Sales $2.10M Miss $2.15M Estimate Benzinga

04:02PM EDT Eiger BioPharmaceuticals Reports Second Quarter 2021 Financial Results and PR Newswire

08:19AM EDT Eiger Unveils FDA Breakthrough Therapy Designation For Avexitide For Congenital Hyperinsulinism Treatment RTTNews

08:03AM EDT Eiger Reports FDA Breakthrough Therapy For Avexitide For Treatment Of Congenital Hyperinsulinism Benzinga

08:01AM EDT Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for PR Newswire

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 3, 2021

04:06PM EDT Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor PR Newswire

Jul 22, 2021

04:06PM EDT Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 PR Newswire

Jul 7, 2021

08:09AM EDT Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RTTNews

08:05AM EDT Amedisys Completes Acquisition Of Home Health And Hospice Assets From VNA RTTNews

08:01AM EDT Eiger BioPharmaceuticals to Present at Ladenburg Thalmann 2021 Virtual PR Newswire

Jul 6, 2021

08:07AM EDT Eiger BioPharma Doses First Patients Dosed With Peginterferon Lambda In Phase 3 TOGETHER Study RTTNews

08:01AM EDT Eiger BioPharmaceuticals Announces First Patients Dosed With Peginterferon Lambda In Phase 3 TOGETHER Study Of Newly Diagnosed COVID-19 Outpatients Benzinga

08:01AM EDT Eiger BioPharmaceuticals Announces First Patients Dosed with Peginterferon PR Newswire

Jul 2, 2021

04:05PM EDT Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule PR Newswire

Jun 29, 2021

08:01AM EDT National Organization of Rare Disorders (NORD) for the Development and FDA Approval of Zokinvy(r) (lonafarnib) PR Newswire

Jun 28, 2021

10:53AM EDT Eiger Bio's Avexitide Reduces Glucose Infusion Requirements To Maintain Normal Glucose Levels In Neonates, Infants Benzinga

08:29AM EDT Eiger Announces Positive Phase 2 Results Of Avexitide In RTTNews

08:23AM EDT Eiger BioPharmaceuticals Highlights Presentation Of Phase 2 Results Of Avexitide In Congenital Hyperinsulinism At American Diabetes Association Virtual 81st Scientific Session Benzinga

08:17AM EDT Eiger Announces Presentation Of Positive Phase 2 Results Of Avexitide In Congenital Hyperinsulinism RTTNews

08:01AM EDT Avexitide in Congenital Hyperinsulinism at the American Diabetes Association Virtual 81st Scientific Session PR Newswire

May 26, 2021

04:05PM EDT Eiger BioPharmaceuticals to Present at Jefferies Virtual Healthcare Conference PR Newswire

May 7, 2021

02:40PM EDT Eiger BioPharmaceuticals shares were trading higher after the company reported Q1 EPS results up from last year. Benzinga

May 6, 2021

04:38PM EDT Eiger BioPharmaceuticals Q1 EPS $0.85 Up From $(0.62) YoY, Sales $3.60M Benzinga

04:02PM EDT Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and PR Newswire

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

May 3, 2021

08:03AM EDT Eiger BioPharmaceuticals Announces Peginterferon Lambda To Added To Multi-Center Phase 3 TOGETHER COVID-19 Study In Brazil Benzinga

08:02AM EDT Eiger BioPharmaceuticals Announces Peginterferon Lambda to be Added to PR Newswire

Apr 29, 2021

08:01AM EDT Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2021 PR Newswire

Apr 22, 2021

08:14AM EDT Eiger BioPharmaceuticals Appoints Veteran Kim Sablich To Board RTTNews

08:02AM EDT Eiger BioPharmaceuticals Appoints Commercial Expert and Industry Veteran Kim PR Newswire

Mar 9, 2021

04:06PM EST Eiger BioPharmaceuticals Q4 EPS $(0.58) Up From $(0.69) YoY Benzinga

04:06PM EST Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial PR Newswire

Feb 23, 2021

11:07AM EST Eiger Bio's Avexitide Shows Reduced Rates Of Hypoglycemia, Rescue In Outpatient Setting Benzinga

08:15AM EST Eiger : Primary And Secondary Endpoints Achieved In Phase 2 PREVENT Study Of Avexitide In Post-Bariatric Hypoglycemia RTTNews

08:07AM EST Eiger Highlights Publication Of Phase 2 PREVENT Study Results Of Avexitide In Post-Bariatric Hypoglycemia In Journal Of Clinical Endocrinology & Metabolism Benzinga

08:03AM EST Post-Bariatric Hypoglycemia in Journal of Clinical Endocrinology & Metabolism PR Newswire

Feb 8, 2021

08:02AM EST Eiger Highlights Publication Of ILIAD Study Results Of Peginterferon Lambda In COVID-19 Published In Lancet Respiratory Medicine 2021 Benzinga

08:01AM EST Eiger Announces ILIAD Study Results of Peginterferon Lambda in COVID-19 PR Newswire

Jan 25, 2021

08:17AM EST Eiger BioPharma Announces U.S. Commercial Availability Of Zokinvy RTTNews

08:03AM EST Eiger BioPharmaceuticals Announces US Commercial Availability Of Zokinvy For Progeria And Processing-Deficient Progeroid Laminopathies Benzinga

08:03AM EST (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies PR Newswire

Jan 11, 2021

11:55AM EST Ameriprise Financial Reports In 13G Filing A Passive Stake Of 12.06% In Eiger BioPharmaceuticals Benzinga

Jan 7, 2021

08:15AM EST Eiger BioPharma : Phase 3 HDV D-LIVR Planned To Complete Enrollment In 2021 RTTNews

08:07AM EST Eiger BioPharmaceuticals Provides Update On 2020 Progress And 2021 Plans Benzinga

08:01AM EST Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans PR Newswire

Jan 4, 2021

11:40AM EST Broadfin Capital Reports In Amended 13G Filing Now Holds 0% Stake In Eiger BioPharmaceuticals Benzinga

Nov 28, 2020

01:08PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

Nov 25, 2020

08:51AM EST Eiger : FDA Oks Zokinvy To Treat Hutchinson-Gilford Progeria Syndrome And Processing-deficient Progeroid Laminopathies RTTNews

08:43AM EST Eiger Biopharmaceuticals Announces FDA Approval Of Zokinvy For Hutchinson-Gilford Progeria Syndrome And Processing-Deficit Progeroid Laminopathies Benzinga

08:42AM EST The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies PR Newswire

Nov 23, 2020

10:02AM EST Eiger BioPharmaceuticals shares were trading higher after the company announced that it has entered into a definitive agreement to sell its Priority Review Voucher (PRV) for a lump sum payment of $95 million. Benzinga

08:05AM EST Eiger BioPharma Sells Priority Review Voucher For $95 Mln RTTNews

08:05AM EST Eiger BioPharmaceuticals Sells Priority Review Voucher For $95M Benzinga

08:01AM EST Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million PR Newswire

Nov 20, 2020

05:54PM EST The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies PR Newswire

08:06AM EST The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga

Nov 17, 2020

08:09AM EST Eiger Announces Positive Peginterferon Lambda-Lonafarnib Combination End Of Study Results From Phase 2 LIFT HDV Study In Late-Breaker Session At The Liver Meeting Digital Experience 2020 Benzinga

08:03AM EST Study Results from Phase 2 LIFT HDV Study in Late-Breaker Session at The Liver Meeting Digital Experience(tm) 2020 PR Newswire

06:41AM EST Eiger BioPharmaceuticals Awarded U.S Patent 10,835,496 'Pharmaceutical compositions comprising lonafarnib and ritonavir' Benzinga

Nov 16, 2020

04:17PM EST Eiger Announces Case Studies Demonstrating Regression Of Liver Fibrosis Following 48 Weeks Of Therapy With Peginterferon Lambda In Patients With Chronic Hepatitis Delta Virus Infection Presented At The Liver Meeting Digital Experience 2020 Benzinga

04:17PM EST Eiger Announces Case Studies Demonstrating Regression Of Liver Fibrosis Following 48 Weeks Of Therapy with Peginterferon Lambda In Patients With Chronic Hepatitis Delta Virus (HDV) Infection Presented At The Liver Meeting Digital Experience 2020 Benzinga

04:05PM EST Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection Presented at The Liver Meeting Digital Experience(tm) 2020 PR Newswire

Nov 13, 2020

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

Nov 11, 2020

08:01AM EST Eiger Bio to Participate in November 2020 Investor Conferences PR Newswire

Nov 5, 2020

04:45PM EST Eiger BioPharmaceuticals Q3 EPS $(0.52) Up From $(0.76) YoY Benzinga

04:06PM EST Eiger BioPharmaceuticals Reports Third Quarter 2020 Financial Results and PR Newswire

Nov 2, 2020

04:35PM EST Eiger Announces Abstracts Highlighting Peginterferon Lambda And Lonafarnib in Chronic Hepatitis Delta Virus (HDV) Infection Accepted For Presentation At The Liver Meeting Digital Experience 2020 Benzinga

04:31PM EST Chronic Hepatitis Delta Virus (HDV) Infection Accepted for Presentation at The Liver Meeting Digital Experience(tm) 2020 PR Newswire

Oct 15, 2020

10:20AM EDT Shares of Eiger BioPharmaceuticals, Inc. (EIGR) are climbing more than 8% Thursday morning after the company announced positive results from the study of its antiviral therapy in Covid-19 patients. RTTNews

08:26AM EDT Eiger Announces Positive Results Of Investigator Sponsored Randomized Controlled Trial; Lambda Accelerated Viral Decline RTTNews

08:12AM EDT Eiger BioPharmaceuticals Announces Results Of Investigator Sponsored Randomized Controlled Trial At University Of Toronto With Peginterferon Lambda In Outpatients With Mild To Moderate COVID-19 Benzinga

08:01AM EDT Randomized Controlled Trial at University of Toronto with Peginterferon Lambda in Outpatients with Mild to Moderate COVID-19 PR Newswire

Oct 1, 2020

05:01PM EDT 4 Sectors Moving Up In Thursday's After-Market Session Benzinga

Sep 28, 2020

02:35PM EDT Mid-Afternoon Market Update: Dow Surges 500 Points; Piedmont Lithium Shares Spike Higher Benzinga

12:10PM EDT Mid-Day Market Update: Perceptron Jumps Following Acquisition News; Inovio Pharmaceuticals Shares Plunge Benzinga

10:37AM EDT Shares of Eiger BioPharmaceuticals, Inc. (EIGR) are losing nearly 15% on Monday morning. RTTNews

10:10AM EDT Mid-Morning Market Update: Markets Open Higher; Cal-Maine Foods Reports Narrower-Than-Expected Loss Benzinga

08:11AM EDT Eiger Announces Results Of Study Of Peginterferon Lambda-1a In Outpatients With Mild And Uncomplicated COVID-19 RTTNews

08:08AM EDT Eiger Announces Results Of Investigator Sponsored Study In Outpatients With Mild And Uncomplicated COVID-19; Says 'No difference was demonstrated in duration of SARS-CoV-2 viral shedding and time to symptom resolution when compared with placebo' Benzinga

08:01AM EDT Eiger Announces Results of Investigator Sponsored Study in Outpatients with PR Newswire

Sep 1, 2020

08:01AM EDT Eiger Bio to Participate in September 2020 Investor Conferences PR Newswire

Aug 31, 2020

08:30AM EDT Eiger Announces Peginterferon Lambda - Lonafarnib Combination End Of Treatment Results From Phase 2 LIFT HDV Study RTTNews

08:28AM EDT Eiger Announces Peginterferon Lambda-Lonafarnib Combination End Of Treatment Results From Phase 2 LIFT HDV Study At Digital International Liver Congress 2020 Benzinga

08:01AM EDT Results from Phase 2 LIFT HDV Study in Late Breaker Session at The Digital International Liver Congress(tm) 2020 PR Newswire

Aug 6, 2020

04:42PM EDT Eiger BioPharmaceuticals Q2 EPS $(0.60) Up From $(0.75) YoY Benzinga

04:06PM EDT Eiger BioPharmaceuticals Reports Second Quarter 2020 Financial Results and PR Newswire

Aug 3, 2020

08:01AM EDT Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor PR Newswire

Share